Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial.


4110 Background: Erlotinib (Tarceva) is a reversible inhibitor of HER1/EGFR tyrosine kinase. It has demonstrated antitumor activity in various epithelial malignancies and additive antitumor effect when combined with chemotherapy drugs. The purpose of this trial was to evaluate the tolerability and preliminary activity of escalating doses of erlotinib given… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.